{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:pasodacigib [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:lunsotogene parvec [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:ontunisertib [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:seldegamadlin [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT01497821: Phase 1 Interventional Completed Renal Cell Adenocarcinoma
(2012)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:emupertinib [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:elecoglipron [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:veludacigib [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:navlimetostat [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:tosposertib [INN]
Source URL:
Class:
CONCEPT